More on Bristol-Myers (BMY +0.3%) Q4: net profit +8.6% to $925M, boosted by a $392M tax benefit...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

More on Bristol-Myers (BMY +0.3%) Q4: net profit +8.6% to $925M, boosted by a $392M tax benefit due to a capital-loss deduction connected to Bristol's ill-fated $2.5B purchase of Inhibitex last year. Sales of Plavix (anti-clotting) crater 97% to $49M, and hypertension drugs Avapro and Avalide also fall, due to patent expirations. Abilify (antipsychoti) +11% to $819M. Expects 2013 adjusted EPS of $1.78-1.88 vs consensus of $1.83, and revenues of $16.2-$17B vs $16.61B.